# Phase I Gene Therapy Clinical Trial Using the Vector rAAV2/5-PBGD for the Treatment of Acute Intermittent Porphyria

> **NCT02082860** · PHASE1 · COMPLETED · sponsor: **Digna Biotech S.L.** · enrollment: 8 (actual)

## Conditions studied

- Acute Intermittent Porphyria

## Interventions

- **GENETIC:** rAAV2/5-PBGD vector dosage 1
- **GENETIC:** rAAV2/5-PBGD vector dosage 2
- **GENETIC:** rAAV2/5-PBGD vector dosage 3
- **GENETIC:** rAAV2/5-PBGD vector dosage 4

## Key facts

- **NCT ID:** NCT02082860
- **Lead sponsor:** Digna Biotech S.L.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11
- **Primary completion:** 2014-07
- **Final completion:** 2014-11
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2014-12-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02082860

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02082860, "Phase I Gene Therapy Clinical Trial Using the Vector rAAV2/5-PBGD for the Treatment of Acute Intermittent Porphyria". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02082860. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*